Current status and recognition of pulmonary surfactant for the treatment of acute respiratory distress syndrome
10.3760/cma.j.issn.2095-428X.2016.18.004
- VernacularTitle:急性呼吸窘迫综合征的肺表面活性物质治疗现状和再认识
- Author:
Chengjun LIU
;
Yuhui DU
- Publication Type:Journal Article
- Keywords:
Pulmonary surfactant;
Acute respiratory distress syndrome;
Child
- From:
Chinese Journal of Applied Clinical Pediatrics
2016;31(18):1372-1375
- CountryChina
- Language:Chinese
-
Abstract:
Exogenous surfactant replacement has been successfully achieved and become standard therapy in neonatal respiratory distress syndrome,but clinical trials in acute respiratory distress syndrome (ARDS) had mixed results.Early studies show that pulmonary surfactant(PS) administration in ARDS can significantly improve oxygenation and decrease mortality,but in recent years,some clinical trials haven't achieve the most substantial benefits to long-term patient outcomes.The inconsistent results of clinical trials may have related to aspects of drug composition,dosing,delivery,and timing.At this time,surfactant therapy cannot be recommended as routine therapy in pediatric ARDS.
